Perifosine | KRX-0401;NSC 639966;NKA17;D21266 | Akt | AmBeed-信号通路专用抑制剂

首页 / / / Akt / Perifosine

哌立福新 /Perifosine 98%

货号：A140384 同义名： KRX-0401;NSC 639966

Perifosine is an Akt inhibitor with IC50 of 4.7 μM, targets pleckstrin homology domain of Akt.

Perifosine 化学结构
CAS号：157716-52-4

Perifosine 3D分子结构
CAS号：157716-52-4

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Perifosine 纯度/质量文件产品仅供科研

货号：A140384 标准纯度： 98% 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell,2024. Ambeed. [ A125712 ]; • Cancer Discov., 2024. Ambeed. [ A285925 ]; • JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]; • JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]; • EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]; 更多 >

Akt 亚型比较

产品名称	Akt ↓ ↑	Akt1 ↓ ↑	Akt2 ↓ ↑	Akt3 ↓ ↑	其他靶点	纯度
Honokiol	✔				MEK	98%
PF-04691502	++++ P-Akt (T308), IC50: 7.5 nM P-Akt (S473), IC50: 3.8 nM					98+%
PHT-427	+ Akt, Ki: 2.7 μM					99%+
Deguelin	✔				PI3K	99%+
TIC10 isomer	✔				ERK	98+%
Perifosine	+ Akt, IC50: 4.7 μM					98%
Miltefosine	✔				PI3K,PKC	98%
Triciribine	+ Akt, IC50: 130 nM					99%+
Uprosertib		+ Akt1, IC50: 180 nM	+ Akt2, IC50: 328 nM	++ Akt3, IC50: 38 nM		99%+
Afuresertib		++++ Akt1, Ki: 0.08 nM	++++ Akt2, Ki: 2 nM	++++ Akt3, Ki: 2.6 nM		99%+
Miransertib		++++ Akt1, IC50: 5 nM	++++ Akt2, IC50: 4.5 nM	++ Akt3, IC50: 16 nM		98+%
GSK-690693		++++ Akt1, IC50: 2 nM	+++ Akt2, IC50: 13 nM	+++ Akt3, IC50: 9 nM		99%+
AT7867		++ Akt1, IC50: 32 nM	++ Akt2, IC50: 17 nM	++ Akt3, IC50: 47 nM	PKA	99%+
AKT inhibitor VIII		++ Akt1, IC50: 58 nM	+ Akt2, IC50: 210 nM	+ Akt3, IC50: 2119 nM		98+%
MK-2206 2HCl		+++ Akt1, IC50: 8 nM	+++ Akt2, IC50: 12 nM	+ Akt3, IC50: 65 nM		99%+
Ipatasertib		++++ Akt1, IC50: 5 nM	++ Akt2, IC50: 18 nM	+++ Akt3, IC50: 8 nM		99%+
AT13148		++ Akt1, IC50: 38 nM	+ Akt2, IC50: 402 nM	++ Akt3, IC50: 50 nM	PKA	98+%
Capivasertib		++++ Akt1, IC50: 3 nM	+++ Akt2, IC50: 8 nM	+++ Akt3, IC50: 8 nM		99%+
A-674563 HCl		+++ Akt1, Ki: 11 nM			PKA	98%
CCT128930			+++ Akt2, IC50: 6 nM		PKA	98+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Perifosine 生物活性

靶点	Akt Akt, IC50:4.7 μM
描述	AKT is the central node of PI3K/AKT/mTOR pathway. It has three functional domains -- a PH domain, a-helical linker domain and central kinase domain. The PH domain can interact with phospholipids produced by the actions of PI3K which serve to home AKT to the cell membrane and transfer to an active conformation^[1]. Perifosine (KRX-0401) is an alkylphospholipid-kind inhibitor of AKT. It can inhibit the binding of the AKT-PH domain to artificial membranes containing 3% PI(3,4)P2 with IC50 value of ~10 μM (measured by SPR) ^[2]. Treatment of perifosine on concentration of 5uM can decrease level of p-AKT-S473 and p-AKT-T308 in PC-3 cells. Stimulated Akt phosphorylation by serum, insulin, IGF-I, EGF, and PDGF was strongly inhibited by 5 μM perifosine for 30 min. Treatment of perifosine (5 μM) can inhibit the membrane localization of the PH domain of Akt^[3]. In vivo study shows that either oral daily (36 mg/kg/d) or weekly (250 mg/kg/week) administration of perifosine can significantly reduce MM tumor growth and increase survival compared with control group in mice^[4]. Clinical trials of perifosine treatment for cancer, including a phase 3 study for colorectal cancer, have been done (see in https://clinicaltrials.gov/).
作用机制	Perifosine inhibits AKT by preventing its translocation from the cytosol to the inner leaflet of the plasma membrane.

Perifosine 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
769-P	0-40 μM	Growth Inhibition Assay	72 h	IC50~5-10 μM	21644050
769-P	0-20 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	21644050
786-0	0-40 μM	Growth Inhibition Assay	72 h	IC50~5 μM	21644050
786-O	0-20 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	21644050

Perifosine 动物研究

Dose

Mice (p.o.): min = 36 mg/kg^[4], max = 200 mg/kg^[6]

Administration

p.o.

Pharmacokinetics

Animal	Nude mice^[7]
Dose	40 mg/kg
Administration	p.o.
C_max	5.7 μg/ml
T_1/2	137 ± 20 h
CL	0.057 l/h/kg
T_max	22 h
AUC	698 ± 19 μg/ml·h
V_d	11.3 l/kg

Perifosine 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01555281	Multiple Myeloma	Phase 1 Phase 2	Active, not recruiting	December 2019	Italy ... 展开 >> Istituto Europeo di Oncologia IEO Milano, Italy, 20141 University of Torino Torino, Italy, 10127 Switzerland Kantonsspital Aarau Aarau, Switzerland, 5001 Kantonsspital Baden Baden, Switzerland, 5404 Istituto Oncologico Svizzera Italiana IOSI Bellinzona, Switzerland, 6500 Inselspital Bern Bern, Switzerland, 3010 Kantonsspital Graubünden Chur, Switzerland, 7000 Kantonsspital Olten Olten, Switzerland, 4600 Kantonsspital St. Gallen St. Gallen, Switzerland, 9007 Regionalspital Thun, Switzerland, 3600 UniversitätsSpital Zürich Zürich, Switzerland, 8091 收起 <<
NCT00055380	Cancer	Phase 1	Completed	-	United States, Maryland ... 展开 >> National Institute of Dental And Craniofacial Research (NIDCR) Bethesda, Maryland, United States, 20892 收起 <<
NCT00053794	Endometrial Cancer ... 展开 >> Sarcoma 收起 <<	Phase 2	Completed	-	Canada, Alberta ... 展开 >> Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada, T2N 4N2 Canada, British Columbia British Columbia Cancer Agency - Vancouver Island Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Mount Sinai Hospital - Toronto Toronto, Ontario, Canada, M5G 1X5 Canada, Quebec Maisonneuve-Rosemont Hospital Montreal, Quebec, Canada, H1T 2M4 收起 <<

Perifosine 参考文献

[1]Keane NA, Glavey SV, et al. AKT as a therapeutic target in multiple myeloma. Expert Opin Ther Targets. 2014 Aug;18(8):897-915.

[2]Perifosine selectively inhibits binding of Akt PH domain to PtdIns(3,4)P2

[3]Kondapaka SB, Singh SS, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003 Nov;2(11):1093-103.

[4]Hideshima T, Catley L, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006 May 15;107(10):4053-62. Epub 2006 Jan 17.

[5]Meuillet EJ, et al. Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain. Curr Med Chem. 2011;18(18):2727-42.

[6]Hennessy BT, Lu Y, et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res. 2007 Dec 15;13(24):7421-31.

[7]Vink SR, Schellens JH, et al. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs. 2005 Aug;23(4):279-86.

Perifosine 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.83mL

2.17mL

1.08mL

21.66mL

4.33mL

2.17mL

Perifosine 技术信息

CAS号	157716-52-4
分子式	C₂₅H₅₂NO₄P
分子量	461.659

别名	KRX-0401;NSC 639966;NKA17;D21266
运输	蓝冰

存储条件

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

H₂O: 100 mg/mL(216.61 mM)，配合低频超声助溶

动物实验配方

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.

产品名称： * 货号：

* 姓名：

* 电话：

* 邮箱： * 公司或机构名称： * 部门：留言给我们：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

Akt	Akt, IC50:4.7 μM

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源

769-P	0-40 μM	Growth Inhibition Assay	72 h	IC50~5-10 μM	21644050
769-P	0-20 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	21644050
786-0	0-40 μM	Growth Inhibition Assay	72 h	IC50~5 μM	21644050
786-O	0-20 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	21644050
A2780	1-30 μM	Cell Viability Assay	48 h	decreases cell viability in a dose dependent manner	25519148
A2780	5 μM	Cytotoxicity Assay	48 h	enhances paclitaxel induced ovarian cancer cell death	21775054
A2780	0-20 μM	Growth Inhibition Assay	48/72 h	IC50 = 3 μm	20405296
A2780cis	0-20 μM	Growth Inhibition Assay	48/72 h	IC50 = 6 μm	20405296
A2780CP		Growth Inhibition Assay		IC50=7.6 μM	23877012
A2780S		Growth Inhibition Assay		IC50=14.5 μM	23877012
A498	0-40 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	21644050
A498	0-20 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	21644050
A549	0.3-10 μM	Growth Inhibition Assay	24/72 h	inhibits cell growth in both time and dose dependent manner	25697899
A549	1/3 μM	Apoptosis Asssay	48 h	induces apoptosis	25697899
A549	3 μM	Function Assay	8 h	blocks AKT activation	25697899
A549	3 μM	Function Assay	8 h	blocks mTORC1, and ERK-MAPK activation combined with MEK-162	25697899
AsPC-1	0-25 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	24519751
AsPC-1	0.5 μM	Function Assay	24 h	inhibits Akt, S6K1, and Erk1/2 phosphorylation	24519751
Bel-7402	5/10/20/40 μM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth in both time and dose dependent manner	20842425
Bel-7402	5/10/20 μM	Function Assay	24 h	results in the accumulation of cell number in the G2/M phase	20842425
Bel-7402	5/10/20 μM	Apoptosis Asssay	24/48 h	induces apoptosis at the long-time exposure	20842425
BJAB	2-10 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	20130960
BJAB	10 μM	Apoptosis Asssay	24/48 h	induces apoptosis time-dependently	20130960
BON1	0-100 μM	Cell Viability Assay	24/72 h	decreases cell viability in both dose and time dependent manner	22499437
BON1	0-10 μM	Apoptosis Asssay	24 h	induces apoptosis dose dependently	22499437
BON1	7.5/10 μM	Function Assay	8 h	decreases the expression of the anti-apoptotic proteins BCL2 and Bcl-XL	22499437
CAKI-1	0-40 μM	Growth Inhibition Assay	72 h	IC50~10 μM	21644050
CAKI-1	0-20 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	21644050
CaOV3	1/5/10 μM	Cell Viability Assay	48 h	decreases cell viability in a dose dependent manner cotreated with paclitaxel	21775054
CLBL-1	0.1–100 μM	Growth Inhibition Assay	48 h	IC50=33.0 μM	24881508
CWR22RV1	10 μM	Cell Viability Assay	24 h	increases sensitivity of human CWR22RV1 cells to radiation	21496273
CWR22RV1	10 μM	Apoptosis Asssay	24 h	enhances radiation induced apoptosis	21496273
CWR22RV1	5 μM	Function Assay	24 h	reduced phosphorylation of Akt significantly	21496273
Ema	0.1–100 μM	Growth Inhibition Assay	48 h	IC50=58.7 μM	24881508
GL-1	0.1–100 μM	Growth Inhibition Assay	48 h	IC50=9.91 μM	24881508
GOT1	0-100 μM	Cell Viability Assay	24/72 h	decreases cell viability in both dose and time dependent manner	22499437
H460	0.3-10 μM	Growth Inhibition Assay	24/72 h	inhibits cell growth in both time and dose dependent manner	25697899
H460	1/3 μM	Apoptosis Asssay	48 h	induces apoptosis	25697899
H460	3 μM	Function Assay	8 h	blocks AKT activation	25697899
H460	3 μM	Function Assay	8 h	blocks mTORC1, and ERK-MAPK activation combined with MEK-162	25697899
HAC2	1-30 μM	Cell Viability Assay	72 h	decreases cell viability in a dose dependent manner	25519148
HCC1806	0-10 μM	Growth Inhibition Assay	48 h	EC50=2.84 ± 0.07 μM	25293576
HepG2	20 μM	Function Assay	24 h	produces an intense cytoplasmic vacuolization corresponding to a notable dilatation of the ER cisterns	25934232
HepG2	20 μM	Function Assay	6/24 h	increases the levels of LC3-II cotreated with CQ	25934232
HepG2	20 μM	Function Assay	6/24 h	decreases LC3-II degradation from 6 h	25934232
HepG2	20/40 μM	Growth Inhibition Assay	24/48 h	inhibits cell growth in both time and dose dependent manner	25934232
HepG2	5/10/20/40 μM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth in both time and dose dependent manner	20842425
HepG2	5/10/20 μM	Function Assay	24 h	results in the accumulation of cell number in the G2/M phase	20842425
HepG2	5/10/20 μM	Apoptosis Asssay	24/48 h	induces apoptosis at the long-time exposure	20842425
HeyA8		Growth Inhibition Assay		IC50=24.3 μM	23877012
HL-60	0-20 μM	Cell Viability Assay	24/48 h	decreases cell viability in both dose and time dependent manner	22407228
HL-60	10 μM	Apoptosis Asssay	24 h	induces apoptosis	22407228
HL-60	2.5/5/10 μM	Function Assay	24 h	decreases Akt and p-Akt levels dose-dependently	22407228
HL-60	2.5/5/10 μM	Function Assay	24 h	induces the phosphorylation of JNK1/2 in a dose dependent manner	22407228
HL-60	2-10 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	20130960
HL-60	10 μM	Apoptosis Asssay	24/48 h	induces apoptosis time-dependently	20130960
HT-29	5 μM	Cytotoxicity Assay	48 h	enhances paclitaxel induced ovarian cancer cell death	21775054
K1	0.1-3 μM	Growth Inhibition Assay	5 d	inhibits cell growth in a dose dependent manner	22090271
K562	20 μM	Function Assay	48 h	induces autophagy	22407228
Kasumi-1	0-20 μM	Cell Viability Assay	24/48 h	decreases cell viability in both dose and time dependent manner	22407228
Kasumi-1	10 μM	Apoptosis Asssay	24 h	induces apoptosis	22407228
Kasumi-1	2.5/5/10 μM	Function Assay	24 h	decreases Akt and p-Akt levels dose-dependently	22407228
Kasumi-1	2.5/5/10 μM	Function Assay	24 h	induces the phosphorylation of JNK1/2 in a dose dependent manner	22407228
KOC7C	1-30 μM	Cell Viability Assay	72 h	decreases cell viability in a dose dependent manner	25519148
M41		Growth Inhibition Assay		IC50=24.7 μM	23877012
M41R		Growth Inhibition Assay		IC50=19.8 μM	23877012
MAVER	2-10 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	20130960
MAVER	10 μM	Apoptosis Asssay	24/48 h	induces apoptosis time-dependently	20130960
MCAS		Growth Inhibition Assay		IC50=12.5 μM	23877012
MDA-MB-231	0-10 μM	Growth Inhibition Assay	48 h	EC50=1.13 ± 0.07 μM	25293576
MGC803	0.75/10 μM	Function Assay	48 h	decreases p-Akt (Ser 473), p-GSK3β (Ser 9), and C-MYC levels	23912246
MIA	0-25 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	24519751
MIA	0.5 μM	Function Assay	24 h	inhibits Akt, S6K1, and Erk1/2 phosphorylation	24519751
MOLM	2-10 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	20130960
MOLM	10 μM	Apoptosis Asssay	24/48 h	induces apoptosis time-dependently	20130960
NCI-H727	0-100 μM	Cell Viability Assay	24/72 h	decreases cell viability in both dose and time dependent manner	22499437
OAW-42	0-40 μM	Growth Inhibition Assay	72 h	IC50~10 μM, inhibits cell growth in a dose dependent manner	20405296
OCI	2-10 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	20130960
OCI	10 μM	Apoptosis Asssay	24/48 h	induces apoptosis time-dependently	20130960
OCUT1	0.1-3 μM	Growth Inhibition Assay	5 d	inhibits cell growth in a dose dependent manner	22090271
OCUT1	3 μm	Function Assay	24 h	causes a dramatic increase in G2/M phase	22090271
OVCAR5		Growth Inhibition Assay		IC50=6.7 μM	23877012
OVCAR8		Growth Inhibition Assay		IC50=31.1 μM	23877012
OVISE	1-30 μM	Cell Viability Assay	48 h	decreases cell viability in a dose dependent manner	25519148
PA-1	0-40 μM	Growth Inhibition Assay	72 h	IC50~25 μM, inhibits cell growth in a dose dependent manner	20405296
PANC-1	0-25 μM	Growth Inhibition Assay	72 h	inhibits cell growth in a dose dependent manner	24519751
PANC-1	0.5 μM	Function Assay	24 h	inhibits Akt, S6K1, and Erk1/2 phosphorylation	24519751
RMG1	1-30 μM	Cell Viability Assay	72 h	decreases cell viability in a dose dependent manner	25519148
RMG1	30 μM	Apoptosis Asssay	24 h	induces apoptosis	25519148
RMG2	1-30 μM	Cell Viability Assay	72 h	decreases cell viability in a dose dependent manner	25519148
RMG2	1-30 μM	Cell Viability Assay	48 h	decreases cell viability in a dose dependent manner	25519148
RMG2	30 μM	Apoptosis Asssay	24 h	induces apoptosis	25519148
SGC7901	0.75/10 μM	Function Assay	48 h	decreases p-Akt (Ser 473), p-GSK3β (Ser 9), and C-MYC levels	23912246
SKOV3	1-30 μM	Cell Viability Assay	48 h	decreases cell viability in a dose dependent manner	25519148
SKOV3	5 μM	Cytotoxicity Assay	48 h	enhances paclitaxel induced ovarian cancer cell death	21775054
SKOV3	0-40 μM	Growth Inhibition Assay	72 h	IC50~30 μM, inhibits cell growth in a dose dependent manner	20405296
SKW6.4	2-10 μM	Growth Inhibition Assay	48 h	inhibits cell growth in a dose dependent manner	20130960
SKW6.4	10 μM	Apoptosis Asssay	24/48 h	induces apoptosis time-dependently	20130960
T24 BC	0.5/1/2.5 μM	Function Assay	3 h	reduces the basal CB tyrosine phosphorylation levels in a dose-dependent manner	26097873
T24 BC	0.5/1/2.5 μM	Cell Viability Assay	24 h	enhances sorafenib-induced cell viability decrease	26097873
T24 BC	2.5 μM	Apoptosis Asssay	24 h	sensitizes BC cells to sorafenib-induced apoptotic	26097873
TykNu		Growth Inhibition Assay		IC50=3.5 μM	23877012
TykNuR		Growth Inhibition Assay		IC50=5.5 μM	23877012
U-87 MG	20 μM	Function Assay	24 h	increases double-membrane bound structures	25934232
U-87 MG	20 μM	Function Assay	6/24 h	increases the levels of LC3-II cotreated with CQ	25934232
U-87 MG	20 μM	Function Assay	6/24 h	increases the autophagic flux at 6 h while inhibits this flux at 24h	25934232
U-87 MG	20/40 μM	Growth Inhibition Assay	24/48 h	inhibits cell growth in both time and dose dependent manner	25934232
U87MG	0-25 μM	Cell Viability Assay	24-96 h	decreases cell viability in both dose and time dependent manner	24065522
UL-1	0.1–100 μM	Growth Inhibition Assay	48 h	IC50=7.01 μM	24881508

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01555281	Multiple Myeloma	Phase 1 Phase 2	Active, not recruiting	December 2019	Italy ... 展开 >> Istituto Europeo di Oncologia IEO Milano, Italy, 20141 University of Torino Torino, Italy, 10127 Switzerland Kantonsspital Aarau Aarau, Switzerland, 5001 Kantonsspital Baden Baden, Switzerland, 5404 Istituto Oncologico Svizzera Italiana IOSI Bellinzona, Switzerland, 6500 Inselspital Bern Bern, Switzerland, 3010 Kantonsspital Graubünden Chur, Switzerland, 7000 Kantonsspital Olten Olten, Switzerland, 4600 Kantonsspital St. Gallen St. Gallen, Switzerland, 9007 Regionalspital Thun, Switzerland, 3600 UniversitätsSpital Zürich Zürich, Switzerland, 8091 收起 <<
NCT00055380	Cancer	Phase 1	Completed	-	United States, Maryland ... 展开 >> National Institute of Dental And Craniofacial Research (NIDCR) Bethesda, Maryland, United States, 20892 收起 <<
NCT00053794	Endometrial Cancer ... 展开 >> Sarcoma 收起 <<	Phase 2	Completed	-	Canada, Alberta ... 展开 >> Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada, T2N 4N2 Canada, British Columbia British Columbia Cancer Agency - Vancouver Island Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Mount Sinai Hospital - Toronto Toronto, Ontario, Canada, M5G 1X5 Canada, Quebec Maisonneuve-Rosemont Hospital Montreal, Quebec, Canada, H1T 2M4 收起 <<
NCT00053781	Melanoma (Skin)	Phase 2	Completed	-	Canada, Alberta ... 展开 >> Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada, T2N 4N2 Canada, Nova Scotia Nova Scotia Cancer Centre Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Princess Margaret Hospital at University Health Network Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Centre Hospitalier de l'Universite de Montreal Montreal, Quebec, Canada, H2L-4M1 McGill University Montreal, Quebec, Canada, H2W 1S6 收起 <<
NCT00019656	Leukemia Lymp... 展开 >>homa Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 收起 <<
NCT00054145	Breast Cancer	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Ottawa Regional Cancer Centre Ottawa, Ontario, Canada, K1H 1C4 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00060437	Prostate Cancer	Phase 2	Completed	-	United States, Maryland ... 展开 >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 收起 <<
NCT00005794	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792-6164 收起 <<
NCT00053924	Pancreatic Cancer	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00064324	Recurrent Adult Soft Tissue Sa... 展开 >>rcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT00431054	Ovarian Cancer	Phase 1	Completed	-	United States, Texas ... 展开 >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01097018	Colorectal Cancer	Phase 3	Completed	-	-
NCT00399126	Neoplasms	Phase 1	Completed	-	United States, Tennessee ... 展开 >> AOI Pharmaceuticals Investigative Site Johnson City, Tennessee, United States, 37604 收起 <<
NCT00399087	Neoplasms	Phase 1	Completed	-	United States, Tennessee ... 展开 >> Investigative Site Johnson City, Tennessee, United States, 37604 收起 <<
NCT00062387	Head and Neck Cancer	Phase 2	Terminated(Administratively co... 展开 >>mplete.) 收起 <<	-	United States, Illinois ... 展开 >> University of Chicago Cancer Research Center Chicago, Illinois, United States, 60637-1470 Decatur Memorial Hospital Cancer Care Institute Decatur, Illinois, United States, 62526 Evanston Northwestern Health Care - Evanston Hospital Evanston, Illinois, United States, 60201-1781 Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 LaGrange Memorial Hospital LaGrange, Illinois, United States, 60525 Cardinal Bernardin Cancer Center at Loyola University Medical Center Maywood, Illinois, United States, 60153 Oncology/Hematology Associates of Central Illinois, P.C. Peoria, Illinois, United States, 61602 Central Illinois Hematology Oncology Center Springfield, Illinois, United States, 62701 United States, Indiana Fort Wayne Medical Oncology and Hematology, Incorporated Fort Wayne, Indiana, United States, 46885-5099 CCOP - Northern Indiana CR Consortium South Bend, Indiana, United States, 46601 United States, Michigan Oncology Care Associates, P.L.L.C. Saint Joseph, Michigan, United States, 49085 United States, Wisconsin Medical College of Wisconsin Cancer Center Milwaukee, Wisconsin, United States, 53226 收起 <<
NCT00301938	Accelerated Phase Chronic Myel... 展开 >>ogenous Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Acute Promyelocytic Leukemia (M3) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Blastic Phase Chronic Myelogenous Leukemia Myelodysplastic/Myeloproliferative Neoplasms Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Relapsing Chronic Myelogenous Leukemia Secondary Acute Myeloid Leukemia T-cell Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 收起 <<
NCT00415064	Multiple Myeloma	Phase 1	Completed	-	United States, Michigan ... 展开 >> Ann Arbor, Michigan, United States, 48109 收起 <<
NCT00398697	Neoplasms	Phase 1	Completed	-	United States, Tennessee ... 展开 >> Johnson City, Tennessee, United States, 37604 收起 <<
NCT02238496	Brain Tumor, Recurrent ... 展开 >> Glioblastoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Mixed Glioma 收起 <<	Phase 2	Unknown	December 2016	United States, New York ... 展开 >> Columbia University Medical Center New York City, New York, United States, 10032 Memorial Sloan-Kettering Cancer Center New York City, New York, United States, 10065 收起 <<
NCT00059982	Pancreatic Cancer	Phase 2	Completed	-	United States, Illinois ... 展开 >> CCOP - Carle Cancer Center Urbana, Illinois, United States, 61801 United States, Indiana CCOP - Northern Indiana CR Consortium South Bend, Indiana, United States, 46601 United States, Iowa CCOP - Iowa Oncology Research Association Des Moines, Iowa, United States, 50309-1016 United States, Massachusetts Tufts - New England Medical Center Boston, Massachusetts, United States, 02111 United States, Minnesota CCOP - Duluth Duluth, Minnesota, United States, 55805 Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 CCOP - Metro-Minnesota Saint Louis Park, Minnesota, United States, 55416 United States, New York MBCCOP-Our Lady of Mercy Cancer Center Bronx, New York, United States, 10466 United States, North Dakota CCOP - Merit Care Hospital Fargo, North Dakota, United States, 58122 United States, Texas CCOP - Scott and White Hospital Temple, Texas, United States, 76508 收起 <<
NCT00399152	Renal Cancer ... 展开 >>GIST 收起 <<	Phase 1	Completed	-	-
NCT00398814	Renal Cancer ... 展开 >>Tumors 收起 <<	Phase 1	Completed	-	-
NCT00058214	Adenocarcinoma of the Prostate... 展开 >> Recurrent Prostate Cancer Stage IIB Prostate Cancer Stage III Prostate Cancer Stage IV Prostate Cancer 收起 <<	Phase 2	Terminated(Did not meet interi... 展开 >>m stopping criteria for continuation to the second stage.) 收起 <<	-	United States, California ... 展开 >> UC Davis Cancer Center Sacramento, California, United States, 95817 收起 <<
NCT00401388	Chondrosarcomas ... 展开 >> Alveolar Soft Part Sarcomas Extra Skeletal Myxoid Chondrosarcomas 收起 <<	Phase 2	Completed	-	-
NCT00422656	Waldenstrom's Macroglobulinemi... 展开 >>a 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00422656	-		Completed	-	-
NCT01051557	-		Terminated	-	-
NCT00399789	Non Small Cell Lung Cancer	Phase 1 Phase 2	Completed	-	United States, Arizona ... 展开 >> AOI Pharmaceuticals Investigative Site Tucson, Arizona, United States, 85704 United States, California AOI Pharmaceuticals Investigative Site Pomona, California, United States, 91767 United States, Florida AOI Pharmaceuticals Investigative Site Aventura, Florida, United States, 33180 AOI Pharmaceuticals Investigative Site Hollywood, Florida, United States, 33021 AOI Pharmaceuticals Investigative Site Lakeland, Florida, United States, 33805 AOI Pharmaceuticals Investigative Site Ormond Beach, Florida, United States, 32174 United States, Georgia AOI Pharmaceuticals Investigative Site Lawrenceville, Georgia, United States, 30045 United States, Illinois AOI Pharmaceuticals Investigative Site Galesburg, Illinois, United States, 61401 United States, Indiana AOI Pharmaceuticals Investigative Site New Albany, Indiana, United States, 47150 United States, Michigan AOI Pharmaceuticals Investigative Site Grand Rapids, Michigan, United States, 49546 AOI Pharmaceuticals Investigative Site Kalamazoo, Michigan, United States, 49048 United States, Montana AOI Pharmaceuticals Investigative Site Billings, Montana, United States, 59101 United States, New Mexico AOI Pharmaceuticals Investigative Site Albuquerque, New Mexico, United States, 87109 United States, New York AOI Pharmaceuticals Investigative Site Albany, New York, United States, 12208 AOI Pharmaceuticals Investigative Site Armonk, New York, United States, 10504 United States, South Carolina AOI Pharmaceuticals Investigative Site Greenville, South Carolina, United States, 29605 United States, Tennessee AOI Pharmaceuticals Investigative Site Chattanooga, Tennessee, United States, 37404 AOI Pharmaceuticals Investigative Site Nashville, Tennessee, United States, 37203 United States, Texas AOI Pharmaceuticals Investigative Site Dallas, Texas, United States, 75237 AOI Pharmaceuticals Investigative Site Dallas, Texas, United States, 75246 AOI Pharmaceuticals Investigative Site Tyler, Texas, United States, 75702 收起 <<
NCT01051557	Adult Anaplastic Astrocytoma ... 展开 >> Adult Anaplastic Oligodendroglioma Adult Diffuse Astrocytoma Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Adult Mixed Glioma Adult Oligodendroglioma Recurrent Adult Brain Neoplasm 收起 <<	Phase 1 Phase 2	Terminated	-	United States, New Jersey ... 展开 >> Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States, 07920 United States, New York Memorial Sloan Kettering Commack Commack, New York, United States, 11725 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00058214	-		Terminated(Did not meet interi... 展开 >>m stopping criteria for continuation to the second stage.) 收起 <<	-	-
NCT00401011	Multiple Myeloma ... 展开 >> Multiple Myeloma in Relapse 收起 <<	Phase 1 Phase 2	Completed	-	-
NCT00391560	Leukemia	Phase 2	Completed	-	-
NCT00398879	Colon Cancer	Phase 2	Completed	-	-
NCT00398710	Waldenström's Macroglobulinemi... 展开 >>a 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00776867	Solid Tumors	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00498966	Kidney Cancer	Phase 2	Completed	-	United States, Kentucky ... 展开 >> Investigative Site Louisville, Kentucky, United States, 40202 United States, New Jersey Investigative Site Morristown, New Jersey, United States, 07962 United States, New York Investigative Site Armonk, New York, United States, 10504 收起 <<
NCT00847366	Non Small Cell Lung Cancer ... 展开 >> Solid Tumors Metastatic Breast Cancer Sarcomas 收起 <<	Not Applicable	Completed	-	-
NCT01002248	Multiple Myeloma	Phase 3	Terminated	-	-
NCT00455559	Gastrointestinal Stromal Tumor... 展开 >>s 收起 <<	Phase 2	Completed	-	-
NCT00448721	Renal Cell Carcinoma	Phase 2	Completed	-	United States, California ... 展开 >> Investigative Site Duarte, California, United States, 91010 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Pennsylvania Investigative Site Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Investigative Site Nashville, Tennessee, United States, 37232 收起 <<
NCT00375791	Multiple Myeloma	Phase 2	Completed	-	United States, California ... 展开 >> Investigative Site Berkeley, California, United States, 94704 Investigative Site Duarte, California, United States, 91010 United States, Georgia Investigative Site Atlanta, Georgia, United States, 30322 United States, Illinois Investigative Site Chicago, Illinois, United States, 60611 United States, Massachusetts Investigative Site Boston, Massachusetts, United States, 02115 United States, Michigan Investigative Site Ann Arbor, Michigan, United States, 48103 United States, Virginia Investigative Site Charlottesville, Virginia, United States, 22908 收起 <<
NCT00873457	Chronic Lymphocytic Leukemia ... 展开 >> Small Lymphocytic Lymphoma 收起 <<	Phase 2	Completed	-	United States, North Carolina ... 展开 >> Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT00389077	Tumors Lympho... 展开 >>mas 收起 <<	Phase 2	Completed	-	-
NCT00873457	-		Completed	-	-
NCT01224730	Cancer	Phase 1	Completed	-	United States, Texas ... 展开 >> Dallas, Texas, United States, 75230 Houston, Texas, United States, 77030 收起 <<
NCT01048580	Colon Cancer	Phase 1	Completed	-	-
NCT00590954	Malignant Gliomas ... 展开 >> CNS Brain Cancer Cancer 收起 <<	Phase 2	Active, not recruiting	May 2019	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT01049841	Pediatric Solid Tumors	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<

哌立福新 /Perifosine 98%

Perifosine 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Perifosine 质控信息

Perifosine 生物活性

Perifosine 细胞研究

Perifosine 动物研究

Perifosine 临床研究

Perifosine 参考文献

Perifosine 实验方案

Perifosine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

哌立福新 /Perifosine 98%

Perifosine 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Perifosine 质控信息

Perifosine 生物活性

Perifosine 细胞研究

Perifosine 动物研究

Perifosine 临床研究

Perifosine 参考文献

Perifosine 实验方案

Perifosine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Perifosine 纯度/质量文件产品仅供科研